Answer
Vandetanib potently inhibits vascular endothelial growth factor receptor‑2 (VEGFR‑2/KDR), epidermal growth factor receptor (EGFR) and RET tyrosine kinases, and also inhibits vascular endothelial receptor‑3 tyrosine kinase at sub‑micromolar concentrations.
Sources for this answer
- Caprelsa 300 mg film-coated tabletsSANOFI · emc · SmPC §5.1 Pharmacodynamic properties · Version 9Document updated
Sources checked